Home › Urothelial (Transitional Cell) Carcinoma › Illinois › Springfield
Urothelial (Transitional Cell) Carcinoma clinical trials in Springfield, IL
3 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Springfield (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RecruitingPhase 3
- Southern Illinois University School of Medicine, Springfield
- Springfield Clinic, Springfield
- Springfield Memorial Hospital, Springfield
Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma
Recruiting
- Southern Illinois University, Springfield
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Southern Illinois University School of Medicine, Springfield
- Springfield Clinic, Springfield
- Springfield Memorial Hospital, Springfield
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Houston, TX18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- San Antonio, TX11 studies
- Boston, MA11 studies
- Austin, TX10 studies
Other studies in Springfield
- Non-Small Cell Lung Cancer13 studies
- Lung Cancer12 studies
- Colorectal Cancer9 studies
- Acute Myeloid Leukemia8 studies
- Breast Cancer8 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Kidney Cancer (Renal Cell Carcinoma)6 studies
- Prostate Cancer6 studies
- Cancer (all types)6 studies
- Bladder Cancer6 studies
- Pancreatic Cancer5 studies
- Melanoma5 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.